Last reviewed · How we verify
mifegyne and cytotec
mifegyne and cytotec is a Antiprogestogen Small molecule drug developed by Western Galilee Hospital-Nahariya. It is currently in Phase 3 development for Medical abortion. Also known as: Comparison of one day dosing to two days dosing.
Mifepristone blocks progesterone receptors, while misoprostol induces uterine contractions.
Mifepristone blocks progesterone receptors, while misoprostol induces uterine contractions. Used for Medical abortion.
At a glance
| Generic name | mifegyne and cytotec |
|---|---|
| Also known as | Comparison of one day dosing to two days dosing |
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Antiprogestogen |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Women's health |
| Phase | Phase 3 |
Mechanism of action
Mifepristone, a progesterone receptor antagonist, is used in combination with misoprostol, a prostaglandin E1 analog, to induce uterine contractions and terminate pregnancy. This combination works by blocking the action of progesterone, which is essential for maintaining pregnancy, and inducing uterine contractions, which helps to expel the embryo or fetus.
Approved indications
- Medical abortion
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Fatigue
- Dizziness
- Bleeding
- Fever
Key clinical trials
- Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage (NA)
- Pain Assessment in MToP Up to 7 WA (during 5h After Misoprostol Intake) (NA)
- Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services (NA)
- Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks (NA)
- Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation (PHASE4)
- Comparison of Two Different Drug Regimens for Medical Treatment of Early Pregnancy Loss (PHASE4)
- Non-surgical Alternatives to Treatment of Failed Medical Abortion (PHASE4)
- Medication Abortion Via Pharmacy Dispensing (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mifegyne and cytotec CI brief — competitive landscape report
- mifegyne and cytotec updates RSS · CI watch RSS
- Western Galilee Hospital-Nahariya portfolio CI
Frequently asked questions about mifegyne and cytotec
What is mifegyne and cytotec?
How does mifegyne and cytotec work?
What is mifegyne and cytotec used for?
Who makes mifegyne and cytotec?
Is mifegyne and cytotec also known as anything else?
What drug class is mifegyne and cytotec in?
What development phase is mifegyne and cytotec in?
What are the side effects of mifegyne and cytotec?
What does mifegyne and cytotec target?
Related
- Drug class: All Antiprogestogen drugs
- Target: All drugs targeting Progesterone receptor
- Manufacturer: Western Galilee Hospital-Nahariya — full pipeline
- Therapeutic area: All drugs in Women's health
- Indication: Drugs for Medical abortion
- Also known as: Comparison of one day dosing to two days dosing
- Compare: mifegyne and cytotec vs similar drugs
- Pricing: mifegyne and cytotec cost, discount & access